E2O Stock Overview
A medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
STRATA Skin Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.76 |
| 52 Week High | US$6.95 |
| 52 Week Low | US$2.74 |
| Beta | 1.37 |
| 1 Month Change | 0% |
| 3 Month Change | 24.50% |
| 1 Year Change | -37.33% |
| 3 Year Change | -67.86% |
| 5 Year Change | -79.77% |
| Change since IPO | -99.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| E2O | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -2.4% | -0.6% |
| 1Y | -37.3% | -4.7% | 14.8% |
Return vs Industry: E2O underperformed the German Medical Equipment industry which returned 8.2% over the past year.
Return vs Market: E2O underperformed the German Market which returned 6.2% over the past year.
Price Volatility
| E2O volatility | |
|---|---|
| E2O Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: E2O has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine E2O's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 99 | Dolev Rafaeli | www.strataskinsciences.com |
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions.
STRATA Skin Sciences, Inc. Fundamentals Summary
| E2O fundamental statistics | |
|---|---|
| Market cap | €13.07m |
| Earnings (TTM) | -€7.52m |
| Revenue (TTM) | €29.61m |
0.4x
P/S Ratio-1.7x
P/E RatioIs E2O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E2O income statement (TTM) | |
|---|---|
| Revenue | US$32.73m |
| Cost of Revenue | US$14.96m |
| Gross Profit | US$17.77m |
| Other Expenses | US$26.09m |
| Earnings | -US$8.31m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 54.30% |
| Net Profit Margin | -25.40% |
| Debt/Equity Ratio | 159.2% |
How did E2O perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/03 07:53 |
| End of Day Share Price | 2024/06/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
STRATA Skin Sciences, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | Boenning & Scattergood, Inc. |
| Jose De Jesus Haresco | Brean Capital |
| null null | CG Capital |